(July 29, 2015) Research published online in the Journal of Clinical Oncology shows that upon completion of primary therapy, women with low-grade serous carcinoma of the ovary (LGSOC) or peritoneum (LGSPC) who are under the age of 35 and have persistent disease face worse outcomes. Researchers at the University of Texas MD Anderson Cancer Center … Continued
(July 23, 2015) New OCRF-funded research demonstrates that combining a PARP-inhibitor with immune therapy results in tumor rejection and long-term survival in a mouse model of BRCA1-deficient ovarian cancer. The study, published in Cancer Immunology Research, was funded by an OCRF Liz Tilberis Early Career Award to Sarah Adams, MD. The benefit of this combination … Continued
(July 21, 2015) A group of Chinese researchers compared clinical characteristics and prognosis between ovarian clear cell carcinoma (CCC) and serous carcinoma (SC), and found that women with ovarian CCC presented at a younger age and early stage. Patients with ovarian CCC also had a longer time to recurrance, but they had similar overall survival … Continued
(July 19, 2015) Ovarian cancer patients who are overweight or obese are often given less chemotherapy per pound of body weight in order to reduce the toxic side effects associated with higher doses, and this in turn may lower their chances of survival, according to a study by researchers at the Rutgers Cancer Institute of … Continued
(July 1, 2015) When bevacizumab was added to standard chemotherapy, ovarian cancer patients with a poor prognosis had an overall survival benefit, according to the ICON7 study published online this week in journal The Lancet Oncology. The study enrolled 1,528 women with newly diagnosed ovarian cancer, high-risk early-stage disease or more advanced disease. The patients were … Continued
Several promising advances in the treatment of ovarian cancer were presented at this year’s annual meeting of the American Society of Clinical Oncologists (ASCO). Below is a report from one of our Research Advocates, Katie Hoody. Click the plus sign to read Katie's report.
(June 19, 2015) In a recent study, funded in part by OCRF grants to Dr. Simon Gayther and Dr. Andrew Berchuck, researchers have made important breakthroughs toward understanding the risk and growth of a certain kind of ovarian cancer, known as mucinous ovarian carcinoma, or MOC. The international study involving 1,644 women with MOC and … Continued
(June 18, 2015) A team of researchers, including OCRF grantees Juan Cubillos-Ruiz, PhD, and Alfredo Perales-Puchalt, MD, have discovered how ovarian cancer shuts down immune system cells that would otherwise act as a first line of defense against the deadly tumor. The findings are published in the June 11 issue of Cell. A therapy that … Continued
(June 17, 2015) Researchers at MD Anderson Cancer Center in Houston have identified a new class of gene mutations that may contribute to outcomes in the treatment of ovarian cancer. Research on the gene family known as ADAMTS could open up a new genetic avenue for the design of ovarian cancer therapies. The findings were … Continued
(June 5, 2015) The Society of Gynecologic Oncology has posted three short videos on YouTube that highlight some of the ovarian cancer research findings presented at the American Society of Clinical Oncology annual meeting last week. Click here to watch the videos, which highlight the results of a number of ovarian cancer clinical trials.
(May 28, 2015) In an effort to study treatment options for high-grade serous ovarian cancer, scientists from the University of Queensland and Sydney’s Millennium Institute collected DNA from 92 patients to find out what makes those cells so resistant to chemotherapy. OCRF Scientific Advisory Committee members Ronny Drapkin, MD, PhD, and Ernst Lengyel, MD, PhD, … Continued
(May 28, 2015) A recent study performed in the UK and New Zealand revealed that having chemotherapy treatments before and after surgery is associated with a higher quality of life when compared to those who undergo surgery before chemotherapy. The study, which included 550 women with Stage III or IV ovarian cancer, concluded that shrinking … Continued
Get email updates about research news, action alerts, and ways to join the fight.
